Is NSRX or NUVL more undervalued in 2026?

CirclFi compares Nasus Pharma Ltd. (NSRX) and Nuvalent, Inc. (NUVL) using 13 institutional-grade valuation models. NSRX has a Quality of Company score of 1.9/10 while NUVL scores 3.7/10.

Which is a better buy — NSRX or NUVL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NSRX and NUVL valuations compare?

NSRX at $3.36 and NUVL at $110.39 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NSRX vs NUVL Valuation Comparison 2026 — Intrinsic Value Analysis

NSRX

Pharmaceutical Preparations

Nasus Pharma Ltd.

Quality

1.9

out of 10

Value Trap

—

Price

$3.36

Last close

Models

7/13

Active

NUVL

Pharmaceutical Preparations

Nuvalent, Inc.

Quality

3.7

out of 10

Value Trap

SAFE

Price

$110.39

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	NSRX Fair Value	NSRX Upside	NUVL Fair Value	NUVL Upside
Bayesian DCF	Intrinsic	$0.78	-76.9%	$31.18	-71.8%
Earnings Power Value	Intrinsic	—	—	$45.79	-56.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$2.27	-32.4%	$94.36	-14.5%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NSRX vs NUVL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NSRX vs NUVL — Which Stock Is More Undervalued?

NUVL scores higher with a 3.7/10 quality rating vs NSRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nasus Pharma Ltd. (NSRX) and Nuvalent, Inc. (NUVL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NSRX currently trades at $3.36 with a QOC of 1.9/10, while NUVL trades at $110.39 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).